@article{pratt_mausert_wilson_emerson_navuluri_pulsipher_brucker_green_bonadonna_bryner_et al._2021, title={A Daily, Respiratory Therapist Assessment of Readiness to Liberate From Venovenous Extracorporeal Membrane Oxygenation in Patients With Acute Respiratory Distress Syndrome}, volume={3}, url={http://dx.doi.org/10.1097/cce.0000000000000584}, DOI={10.1097/cce.0000000000000584}, abstractNote={
            Objectives:
            We assessed the effect of implementing a protocol-directed strategy to determine when patients can be liberated from venovenous extracorporeal membrane oxygenation on extracorporeal membrane oxygenation duration, time to initiation of first sweep-off trial, duration of mechanical ventilation, ICU length of stay, hospital length of stay, and survival to hospital discharge.
          }, number={12}, journal={Critical Care Explorations}, publisher={Ovid Technologies (Wolters Kluwer Health)}, author={Pratt, Elias H. and Mausert, Sarah and Wilson, Michael D. and Emerson, Logan J. and Navuluri, Neelima and Pulsipher, Aaron M. and Brucker, Amanda and Green, Cynthia L. and Bonadonna, Desiree K. and Bryner, Benjamin S. and et al.}, year={2021}, month={Dec}, pages={e0584} }
 @article{mahmood_abbott_nostrand_bechara_gonzalez_brucker_green_polage_2021, title={Low utilisation of bronchoscopy to assess COVID-19 respiratory infection: a multicenter experience}, volume={8}, url={http://dx.doi.org/10.1136/bmjresp-2021-000962}, DOI={10.1136/bmjresp-2021-000962}, abstractNote={ObjectiveFor the diagnosis of COVID-19, the yield of nasopharyngeal (NP) swabs is unclear, and bronchoalveolar lavage (BAL) is obtained to confirm the diagnosis. We assessed the utilisation of bronchoscopy for COVID-19 diagnosis in a multicenter study and compared the diagnostic yield of BAL versus NP swabs.}, number={1}, journal={BMJ Open Respiratory Research}, publisher={BMJ}, author={Mahmood, Kamran and Abbott, Matt and Nostrand, Keriann Van and Bechara, Rabih and Gonzalez, Anne V and Brucker, Amanda and Green, Cynthia L and Polage, Christopher R}, year={2021}, month={Jul}, pages={e000962} }
 @article{brucker_lu_west_yu_hsiao_hsiao_lin_magnusson_sullivan_szatkiewicz_et al._2020, title={Association test using Copy Number Profile Curves (CONCUR) enhances power in rare copy number variant analysis}, volume={16}, ISSN={["1553-7358"]}, url={https://doi.org/10.1371/journal.pcbi.1007797}, DOI={10.1371/journal.pcbi.1007797}, abstractNote={Copy number variants (CNVs) are the gain or loss of DNA segments in the genome that can vary in dosage and length. CNVs comprise a large proportion of variation in human genomes and impact health conditions. To detect rare CNV associations, kernel-based methods have been shown to be a powerful tool due to their flexibility in modeling the aggregate CNV effects, their ability to capture effects from different CNV features, and their accommodation of effect heterogeneity. To perform a kernel association test, a CNV locus needs to be defined so that locus-specific effects can be retained during aggregation. However, CNV loci are arbitrarily defined and different locus definitions can lead to different performance depending on the underlying effect patterns. In this work, we develop a new kernel-based test called CONCUR (i.e., copy number profile curve-based association test) that is free from a definition of locus and evaluates CNV-phenotype associations by comparing individuals’ copy number profiles across the genomic regions. CONCUR is built on the proposed concepts of “copy number profile curves” to describe the CNV profile of an individual, and the “common area under the curve (cAUC) kernel” to model the multi-feature CNV effects. The proposed method captures the effects of CNV dosage and length, accounts for the numerical nature of copy numbers, and accommodates between- and within-locus etiological heterogeneity without the need to define artificial CNV loci as required in current kernel methods. In a variety of simulation settings, CONCUR shows comparable or improved power over existing approaches. Real data analyses suggest that CONCUR is well powered to detect CNV effects in the Swedish Schizophrenia Study and the Taiwan Biobank.}, number={5}, journal={PLOS COMPUTATIONAL BIOLOGY}, publisher={Public Library of Science (PLoS)}, author={Brucker, Amanda and Lu, Wenbin and West, Rachel Marceau and Yu, Qi-You and Hsiao, Chuhsing Kate and Hsiao, Tzu-Hung and Lin, Ching-Heng and Magnusson, Patrik K. E. and Sullivan, Patrick F. and Szatkiewicz, Jin P. and et al.}, editor={Ma, JianEditor}, year={2020}, month={May} }
 @article{gallagher_zhao_brucker_massengill_kramer_poon_goldstein_2020, title={Implementation and Continuous Monitoring of an Electronic Health Record Embedded Readmissions Clinical Decision Support Tool}, volume={10}, url={https://doi.org/10.3390/jpm10030103}, DOI={10.3390/jpm10030103}, abstractNote={Unplanned hospital readmissions represent a significant health care value problem with high costs and poor quality of care. A significant percentage of readmissions could be prevented if clinical inpatient teams were better able to predict which patients were at higher risk for readmission. Many of the current clinical decision support models that predict readmissions are not configured to integrate closely with the electronic health record or alert providers in real-time prior to discharge about a patient’s risk for readmission. We report on the implementation and monitoring of the Epic electronic health record—“Unplanned readmission model version 1”—over 2 years from 1/1/2018–12/31/2019. For patients discharged during this time, the predictive capability to discern high risk discharges was reflected in an AUC/C-statistic at our three hospitals of 0.716–0.760 for all patients and 0.676–0.695 for general medicine patients. The model had a positive predictive value ranging from 0.217–0.248 for all patients. We also present our methods in monitoring the model over time for trend changes, as well as common readmissions reduction strategies triggered by the score.}, number={3}, journal={Journal of Personalized Medicine}, publisher={MDPI AG}, author={Gallagher, David and Zhao, Congwen and Brucker, Amanda and Massengill, Jennifer and Kramer, Patricia and Poon, Eric G. and Goldstein, Benjamin A.}, year={2020}, month={Aug}, pages={103} }
 @article{fanaroff_prather_brucker_wojdyla_davidson-ray_mark_williams_barefoot_weisz_ben-yehuda_et al._2019, title={Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85061359482&partnerID=MN8TOARS}, DOI={10.1016/j.amjcard.2019.01.036}, abstractNote={Greater optimism regarding recovery from chronic illness is associated with improved quality of life and clinical outcomes. We performed a post-hoc analysis on the association between optimism and outcomes in Ranolazine in Patients with Incomplete Revascularization after Percutaneous Coronary Intervention (RIVER-PCI), a randomized trial in patients with chronic angina pectoris who had incomplete revascularization following percutaneous coronary intervention. At baseline, patients answered how much they agreed with the phrase, "I am optimistic about my future and returning to a normal lifestyle." We evaluated the association between baseline optimism and time to ischemia-driven hospitalization or revascularization using a Cox model, and the association between baseline optimism and change in frequency of angina pectoris using a mixed measures model. Of 2,389 patients, 782 (33.2%) were very optimistic ("strongly agree"), 1,000 (42.4%) were optimistic ("agree"), 451 (19.1%) were neutral ("undecided"), and 123 (5.2%) were not optimistic ("disagree" or "strongly disagree"). Very optimistic patients had a lower prevalence of co-morbidities and less severe angina at baseline than less optimistic patients. The rate of ischemia-driven revascularization or hospitalization was higher in neutral and not optimistic patients compared with very optimistic patients; this finding persisted after adjustment for co-morbidities and baseline angina frequency (hazard ratio 1.42, 95% confidence interval 1.14 to 1.77 for neutral vs very optimistic; hazard ratio 1.38, 95% confidence interval 0.98 to 1.94 for not optimistic vs very optimistic). Neutral and not optimistic patients also had less improvement in angina than very optimistic patients. In conclusion, in patients with angina, those with more self-reported optimism had better health status outcomes. Whether structured interventions targeting optimism improve outcomes in these patients warrants further study.}, journal={American Journal of Cardiology}, author={Fanaroff, A.C. and Prather, K. and Brucker, A. and Wojdyla, D. and Davidson-Ray, L. and Mark, D.B. and Williams, R.B. and Barefoot, J. and Weisz, G. and Ben-Yehuda, O. and et al.}, year={2019} }
 @article{marquis-gravel_thiele_jones_smalling_cohen_perera_pijls_fanaroff_brucker_chiswell_et al._2019, title={Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized Controlled Trial)}, volume={123}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85059823953&partnerID=MN8TOARS}, DOI={10.1016/j.amjcard.2018.12.027}, abstractNote={International variability in infarct size following acute anterior ST-elevation myocardial infarction without shock treated with primary percutaneous coronary intervention (PCI) has been little studied. Patients enrolled in the Counterpulsation to Reduce Infarct Size pre‐PCI for Acute Myocardial Infarction international randomized trial were analyzed according to their region of enrollment: United States (US) (n = 60), Europe/Australia (EU/AU) (n = 104), or India (n = 123). Cardiac magnetic resonance imaging was performed 3–5 days after PCI to assess infarct size, expressed as percentage of left ventricular mass, and analyzed by an imaging core laboratory. The relation between infarct size and region was modelled using multivariable linear regression adjusting for time from symptom onset to first hospital contact, myocardial infarction severity, and baseline characteristics. Infarct size was 36.4% of left ventricular mass in US patients (95% confidence interval [CI] 31.5 to 41.4), 36.5% (95% CI 32.6 to 40.4) in EU/AU patients, and 44.7% (95% CI 41.1 to 48.2) in patients from India (p = 0.01). In multiplicity-adjusted regression analysis, mean infarct size in patients from India was higher than in US patients (mean difference of 8.3%; 95% CI 0.7 to 15.8; p = 0.03), and EU/AU patients (mean difference of 8.2%; 95% CI 1.6 to 14.8; p = 0.01). There was no significance difference in infarct size between patients from the EU/AU and the US (mean difference of 0.1%; 95% CI −7.5 to 7.4; p = 0.99). ln conclusion, in patients with anterior ST-elevation myocardial infarction without cardiogenic shock treated with primary PCI, infarct size was larger in India compared to the United States and EU/AU, even after adjustment for performance metrics, including time to treatment, and other potential confounders. Future studies are needed to better elucidate this discrepancy. International variability in infarct size following acute anterior ST-elevation myocardial infarction without shock treated with primary percutaneous coronary intervention (PCI) has been little studied. Patients enrolled in the Counterpulsation to Reduce Infarct Size pre‐PCI for Acute Myocardial Infarction international randomized trial were analyzed according to their region of enrollment: United States (US) (n = 60), Europe/Australia (EU/AU) (n = 104), or India (n = 123). Cardiac magnetic resonance imaging was performed 3–5 days after PCI to assess infarct size, expressed as percentage of left ventricular mass, and analyzed by an imaging core laboratory. The relation between infarct size and region was modelled using multivariable linear regression adjusting for time from symptom onset to first hospital contact, myocardial infarction severity, and baseline characteristics. Infarct size was 36.4% of left ventricular mass in US patients (95% confidence interval [CI] 31.5 to 41.4), 36.5% (95% CI 32.6 to 40.4) in EU/AU patients, and 44.7% (95% CI 41.1 to 48.2) in patients from India (p = 0.01). In multiplicity-adjusted regression analysis, mean infarct size in patients from India was higher than in US patients (mean difference of 8.3%; 95% CI 0.7 to 15.8; p = 0.03), and EU/AU patients (mean difference of 8.2%; 95% CI 1.6 to 14.8; p = 0.01). There was no significance difference in infarct size between patients from the EU/AU and the US (mean difference of 0.1%; 95% CI −7.5 to 7.4; p = 0.99). ln conclusion, in patients with anterior ST-elevation myocardial infarction without cardiogenic shock treated with primary PCI, infarct size was larger in India compared to the United States and EU/AU, even after adjustment for performance metrics, including time to treatment, and other potential confounders. Future studies are needed to better elucidate this discrepancy.}, number={7}, journal={American Journal of Cardiology}, author={Marquis-Gravel, G. and Thiele, H. and Jones, W.S. and Smalling, R.W. and Cohen, M. and Perera, D. and Pijls, N. and Fanaroff, A. and Brucker, A. and Chiswell, K. and et al.}, year={2019}, pages={1026–1034} }
 @article{siddiqui_rajagopal_brucker_chiswell_christopher_alenezi_mandawat_rivera_arges_tapson_et al._2018, title={Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension}, volume={122}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85050965560&partnerID=MN8TOARS}, DOI={10.1016/j.amjcard.2018.05.019}, abstractNote={In pulmonary hypertension (PH), measurement of various echocardiographic parameters that assess right heart function is recommended by current clinical guidelines. Limited data exists on the combined value of clinical and echocardiographic parameters in precapillary PH in the modern era of therapy. We examined the association of clinical and echocardiographic parameters with surrogate outcomes (6-minute walk distance) and hard outcomes (hospitalization or death) in patients with precapillary PH. A cohort of patients with an established diagnosis of precapillary PH who underwent transthoracic echocardiography at the Duke Echo Lab were prospectively enrolled from 2010 to 2014. Univariable and multivariable models were constructed to examine the relation of clinical and echocardiographic parameters with surrogate and hard outcomes. Of the 98 patients with analyzable echocardiograms with good image quality, 85 were woman, mean age was 59.4 years, and 47% had ≥World Health Organization functional class III symptoms. The mean 6-minute walk distance was 354(±132) m, and 83% were on pulmonary arterial hypertension medications. At 24 months, the cumulative incidence rate for hospitalization or death was 47%. In univariable analyses, the REVEAL (Registry to Evaluate Early and Long-term PAH Disease Management) risk score (HR 1.72 per 1 SD (2.81) increment, 95% CI 1.34, 2.22; p=<0.001), RV global longitudinal strain (RVGLS) (HR 1.54 per 1 SD (5.31) worsening, 95% CI , 2.12; p=0.008) and log-2 NT proBNP (HR 1.43 per 1-fold increase, 95% CI 1.25, 1.63; p=<0.001) were significantly associated with hospitalization or death.}, number={5}, journal={American Journal of Cardiology}, author={Siddiqui, I. and Rajagopal, S. and Brucker, A. and Chiswell, K. and Christopher, B. and Alenezi, F. and Mandawat, A. and Rivera, D. and Arges, K. and Tapson, V. and et al.}, year={2018}, pages={872–878} }
 @article{pagidipati_mudrick_chiswell_brucker_peterson_douglas_2018, title={Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease}, volume={206}, ISSN={["1097-5330"]}, url={http://www.scopus.com/inward/record.url?eid=2-s2.0-85054558882&partnerID=MN8TOARS}, DOI={10.1016/j.ahj.2018.09.014}, abstractNote={Patients with nonobstructive coronary artery disease (CAD) have worse outcomes compared with those without CAD; however, few studies have compared the intermediate- and long-term impact of CAD severity as a function of patient sex. We evaluated 5-year and long-term all-cause mortality of women and men undergoing elective coronary angiography at a single center by degree of CAD: no CAD (1%-24% stenosis), nonobstructive CAD (25%-69% epicardial stenosis or 25%-49% left main stenosis), or obstructive CAD (epicardial stenosis ≥70% or left main stenosis ≥50%), both overall and after adjusting for baseline clinical risk factors using Cox proportional-hazards models. Between January 1986 and July 2010, 8,766 women and 11,638 men underwent angiography and were followed for a median of 9.2 years. The majority (67%) of women had no CAD or nonobstructive CAD, whereas the majority of men had obstructive CAD (56%, P < .001). In both sexes, increasing CAD was associated with increased 5-year risk of mortality. Risk-adjusted hazard ratios (vs no CAD) for women were 1.36 (95% CI, 1.16-1.60) and 1.86 (1.61-2.16) for nonobstructive and obstructive CAD, respectively; corresponding hazard ratios for men were 1.24 (1.06-1.45) and 1.38 (1.20-1.59). After risk adjustment, 5-year mortality risk was higher in men than in women at all levels of CAD severity. The relationships between severity of CAD and mortality risk during long-term follow-up in women and men were similar to the 5-year relationships above. Although women undergoing elective catheterization have less severe CAD than men, nonobstructive CAD is prevalent in both sexes and carries a worse prognosis than no CAD. These data suggest a need for further investigation to establish optimal therapies for this at-risk group of patients with nonobstructive CAD.}, journal={AMERICAN HEART JOURNAL}, author={Pagidipati, Neha J. and Mudrick, Daniel W. and Chiswell, Karen and Brucker, Amanda and Peterson, Eric D. and Douglas, Pamela S.}, year={2018}, month={Dec}, pages={51–60} }